期刊文献+

贫血患儿血清生长分化因子15水平及其鉴别重型β地中海贫血的临床意义 被引量:7

Measurement of serum GDF15 levels in various childhood anemias and its clinical application in the differential diagnosis of β-thalassemia major
下载PDF
导出
摘要 目的研究不同类型贫血患儿血清生长分化因子15(GDF15)水平及其与贫血程度、红系造血、铁代谢的相关性,以及在重型β地中海贫血(SBT)鉴别中的临床价值。方法入选85例不同类型的贫血患儿,包括缺铁性贫血(IDA)19例,慢性病贫血(ACD)8例,再生障碍性贫血(AA)24例,重型β地中海贫血(SBT)17例,非SBT溶血性贫血(nonSBT HA)17例,另选21例健康体检儿童为对照组;采用ELISA方法测定血清GDF15水平,并分析其与血红蛋白(Hb)水平、网织红细胞参数和铁代谢指标的相关关系,ROC曲线分析血清GDF15水平对于儿童SBT的诊断价值。结果各贫血亚组和对照组之间血清GDF15水平的差异有统计学意义(H=56.75,P〈0.001)。除ACD外,其他贫血亚组的血清GDF15水平均高于对照组,SBT组GDF15水平均高于对照组和其他贫血亚组,差异有统计学意义(P’〈0.003),其中SBT组患儿血清GDF15中位浓度为对照组的28倍。贫血患儿GDF15与Hb水平呈显著负相关(rs=–0.429,P〈0.01)。贫血患儿GDF15水平与网织红细胞比例、网织红细胞绝对计数、RI和RPI显著正相关(rs=0.264-0.375,P均〈0.05)。贫血患儿GDF15水平与SF、SI和TS均显著正相关(rs=0.473-0.717,P均〈0.01);与Tf和TIBC呈负相关(rs=–0.345、–0.349,P均〈0.05)。血清GDF15水平诊断重型β地中海贫血的ROC曲线下面积(AUC)为0.969(95%CI:0.937-1.0;P〈0.01),如以血清GDF15浓度5 000 pg/ml作为截断值,诊断SBT的特异度为98.5%。结论血清GDF15水平显著升高是SBT患儿极为显著的血液生化特征,可能与骨髓无效造血密切相关;血清GDF15水平检测有助于SBT与其他类型溶血性贫血的鉴别。 Objective To measure the serum GDF15 levels, to explore the possible correlations between serum GDF15 levels to anemia severity, hematopoietic activity and iron parameters in various types of childhood anemia, and to investigate its clinical application in the differential diagnosis of severe beta thalassemia(SBT). Methods Eighty-five children with various types of anemia were enrolled into this study, including 19 cases of IDA, 8 cases of ACD, 24 cases of AA, 17 cases of severe β-thalassemia(SBT) and 17 cases of hemolytic anemia other than SBT(non-SBT HA). In addition, 21 age- and sex- matched healthy children were recruited as controls. Serum GDF15 levels both in anemic and healthy control subjects were determined by GDF15 Quantikine DGD 150 ELISA assay. Correlations were made between GDF15 levels and Hb concentrations, reticulocyte indices and iron parameters. The diagnostic significance of serum GDF15 determination in the differential diagnosis of SBT was evaluated by ROC analysis. Results With the exception of ACD, serum GDF15 level was significantly higher in each anemic subgroup than that in control group(all P0.001). Median and range of serum GDF15 concentrations in hemolytic group(HA) were 2299 pg/ml and 444-13368 pg/ml respectively, which were greatly higher than that in iron deficiency anemia(IDA) and aplastic anemia(AA)(both P0.001). Notably, GDF15 levels were remarkably elevated in SBT, with median and maximal concentrations being 7480 pg/ml and 13368 pg/ml, up to 28-fold and 50-fold increase respectively as compared to median concentration in control group, and were also significantly higher than that in non-SBT HA group(P〈0.0001). Serum GDF15 levels were negatively correlated to Hb concentrations both in overall anemia and HA groups(with rank correlation coefficients of-0.4286 and-0.4903, and P 〈0.0001 and 0.0032 respectively). Similarly, serum GDF15 levels were positively correlated to all 4 types of reticulocyte indices in the overall anemia group. Nevertheless, no correlation could be documented in each anemia subgroup. As for the 48 cases of children with measurement of iron parameters, GDF15 levels were positively correlated to serum ferritin(SF), serum iron(SI) and transferrin saturation(TS), with P values of 0.0005, 〈0.0001 and 〈0.0001 respectively. While for 23 cases with hemolytic anemia who had iron investigation results, GDF15 was also positively correlated to SI and TS, with P values of 0.0009 and 0.0042 respectively. Finally, the precision of SBT diagnosis based on serum GDF15 determination was 93.7%-100%(95% confidence interval). With serum GDF15 concentration of 5000 pg/ml as the cutoff point, the specificity of SBT diagnosis was 98.5%. Conclusions As expected, childhood β-thalassemia major in China is also characterized by remarkably elevated serum GDF15 levels, which might be intimately associated with marked bone marrow ineffective erythropoiesis. Determination of serum GDF15 is of great significance in the differential diagnosis of β-thalassemia major.
出处 《临床儿科杂志》 CAS CSCD 北大核心 2015年第5期417-422,共6页 Journal of Clinical Pediatrics
基金 四川省科学技术应用基础项目(No.2015GJ0044)
关键词 生长分化因子15 贫血 铁代谢 鉴别诊断 growth differentiation factor 15 anemia iron metabolism differential diagnosis
  • 相关文献

参考文献32

  • 1Mimeault M, Batra SK. Divergent molecular mechanisms anderlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer [J]. J Cell Physiol, 2010, 224(3): 626-635.
  • 2Berit SN, Johen H, CookA, et al. The TGF-b superfamily cytokine, MIC-1/GDF15. a pleotrophic cytokine with roles in inflammation, cancer and metabolism [J]. Growth Factors, 2011, 29(5): 187-195.
  • 3Unsicker K, Spittau B, Krieglstein K. The mul~ple facets of the TGF-b family cytokine growth/differentiation factor-15/ macrophage inhibitory cytokine-1 [J]. Cytokine Growth Factor Rev, 2013, 24(4) : 373-384.
  • 4Corre J, Hebraud B, Bourin P. Concise review: growth differentiation factor 15 in pathology: a clinical role? [J]. Stem Cells Transl Med, 2013, 2(12): 946-952.
  • 5Collinson P. The role of cardiac biomarkers in cardiovascu- lar disease risk assessment [J]. Curr Opin Cardiol, 2014, 29(4): 366-371.
  • 6Xu X, Li Z, Gao W. Growth differentiation factor 15 in cardiovascular diseases: from bench to bedside [J]. Bio- markers, 2011, 16(6): 466-475.
  • 7Hochholzer W, Morrow DA, Giugliano RP. Novel bio- markers in cardiovascular disease: update 2010 [J]. Am Heart J, 2010, 160(4): 583-594.
  • 8Tanno T, Bhanu NV, Oneal PA, et al. High levels ofGDF15 in thalassemia suppress expression of the iron regulato- ryproteinhepcidin [J]. Nat Med, 2007, 13(9): 1096-1101.
  • 9Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I [J]. Blood, 2008, 112(13): 5241-5244.
  • 10Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dyseryth- ropoietic anaemia (CDA) type II [J]. J Mol Med (Berl), 2011, 89(8): 811-816.

二级参考文献41

  • 1Gupta S, Weitzman S. Primary and secondary hemophago- cytic lymphohistiocytosis: clinical features, pathogenesis and therapy [J]. Expert Rev Clin Immunol, 2010, 6(1): 137-154.
  • 2Pachlopnik Schmid J, Cote M, Menager MM, et al. Inher- ited defects in lymphocyte cytotoxic activity [J]. Immunol Rev, 2010, 235(1): 10-23.
  • 3Henter JI, Horne A, Arico M, et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis [J]. Pediatr Blood Cancer, 2007, 48(2): 124-131.
  • 4Fairlie WD, Moore AG, Bauskin AR, etal. MIC-1 is a nov- el TGF - β superfamily cytokine associated with macrophage activation [J]. J Leukoc Biol, 1999, 65(1): 2-5.
  • 5Mimeault M, Batra SK. Divergent molecular mechanisms underlying the pleiotropic functions of maerophage inhibi-tory cytokine-1 in cancer [J]. J Cell Physiol, 2010, 22(3): 626-635.
  • 6Tanno T, Bhanu NV, Oneal PA, et al. High levels of GDF15 in thalassemia suppresses expression of the iron regulatory protein hepcidin [J]. Nat Med, 2007, 13(9): 1096-1101.
  • 7Casanovas G, Swinkels DW, Altamura S, et al. Growth differentiation factor 15 in patients with congenital dysery- thropoietic anaemia (CDA) type II [J]. J Mol Med (Berl), 2011, 89(8): 811-816.
  • 8Tamary H, Shalev H, Perez-Avraham G, et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I [J]. Blood, 2008, 112(13): 5241-5244.
  • 9Tanno T, Noel P, Miller JL. Growth differentiation factor 15 in erythroid health and disease [J]. Curr Opin Hematol,2010, 17(3): 184-190.
  • 10Torti FM, Torti SV. Regulation of ferritin genes and protein [J]. Blood, 2002, 99(10): 3505-3516.

共引文献4

同被引文献70

  • 1Musallam K M, Cappellini M D, Taher A T.Iron overload in 13-thalassemia intermedia: An emerging concern[J].Curr Opin Hematol, 2013, 20 ( 3 ) : 187-192.
  • 2Pennell D J, Porter J B, Piga A, et al.Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine[J].Am J Hematol, 2015, 90 ( 2 ) : 91-96.
  • 3Musallam K M, Cappellini M D, Taher A T.Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with 13-thalassemia intermedia[J].Blood Cells Mol Dis, 2013, 51 ( 1 ) : 35-38.
  • 4Saito H, Hayashi H.Transformation rate between ferritin and hemosiderin assayed by serum ferritin kinetics in patients with normal iron stores and iron overload[J].Nagoya J Med Sci, 2015, 77 ( 4 ) : 571-583.
  • 5Kontoghiorghe C N, Kolnagou A, Kontoghiorghes G J.Phytochelators intended for clinical use in iron overload, other diseases of iron imbalance and free radical pathology[J].Molecules, 2015, 20 ( 11 ) : 20841-20872.
  • 6Darwish S F, EI-Bakly W M, EI-Naga R N, et al.Antifibrotic mechanism of deferoxamine in concanavalin A induced-liver fibrosis: Impact on interferon therapy[J].Biochem Pharmacol, 2015, 98 ( 1 ) : 231-242.
  • 7Choi C W, Lee J, Lee H J.Deferoxamine improves alveolar and pulmonary vascular development by upregulating hypoxia- inducible factor-1 ot in a rat model of bronchopulmonary dysplasia[J].J Korean Med Sci, 2015, 30 ( 9 ) : 1295-1301.
  • 8朱易萍.地中海贫血的规范化输血治疗[J].中国输血杂志,2010,23(1):4-6. 被引量:16
  • 9王菊芳.剖宫产与阴道分娩对乳汁分泌的影响及护理干预[J].现代中西医结合杂志,2010,19(17):2181-2182. 被引量:27
  • 10陆祝选,钟春平,蔡海岩.南宁市采供血现状调查分析[J].广西医学,2011,33(5):612-614. 被引量:20

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部